Amgen Inc. (AMGN)财务
NASDAQ · Healthcare · Drug Manufacturers - General · 员工31,500人 · CEO Robert A. Bradway
- 股价
- $466.01 +1.15%
- 市值
- $2520亿
- 企业价值
- $2950亿
- 最近财报
- Q2 '26 2026-08-05提交
- 下次财报
- 2026-11-03 EPS预期 $5.79
营收(TTM)$381亿+9.2% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)33.2%+9.7 百分点 对比去年同期营业利润 $126亿
净利润(TTM)$87.4亿+32.1% 对比去年同期税后,含营业外收益
自由现金流(TTM)$102亿-4.1% 对比去年同期资本支出 $23亿
稀释EPS(TTM)$16.09+31.6% 对比去年同期最近4个季度之和
净现金-$433亿+10.1% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $2520亿 EV $2950亿
- 营收
- $381亿 过去12个月
- 营收增速
- +6% FY2026年一致预期
- 净利润率
- 22.9% 净利润 / 营收,TTM
- P/E
- 28.7× 预期 20.2×(FY2026)
- P/S
- 6.6× 股价 / 营收,TTM
- EV / EBITDA
- 16.8× TTM
- 自由现金流
- $102亿 过去12个月
- 净利润
- $87.4亿 过去12个月
- 营收预期
- $390亿 FY2026年一致预期
- 盈利
- 2026-11-03 营收预期 $101亿
- 股息
- $9.94 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-04):营收超预期6.7%,EPS 超预期11.9%营收$101亿,预期$94.3亿(+6.7%);EPS $6.29,预期$5.62(+11.9%)。
- 营收增长平稳:同比9.7%Q2 '26营收$101亿,此前四个季度的平均值为9.1%。
- 营业利润率33.2%(TTM),较去年同期+9.7 百分点营收增长9.2%,营业利润增长54.6%。
- 税前利润的23.0%被营业外亏损吞噬税前利润$103亿,营业利润$126亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 资本支出占营收的6.0%(去年为4.0%)最近4个季度投入$23亿(同比+63.6%)。自由现金流$102亿,相当于净利润的116.4%。
- 股东回报$52.9亿 = 自由现金流的51.9%回购$0(去年为$2亿),股息$52.9亿,股权激励$4.92亿(TTM)。
- 稀释股数一年内增加0.6%Q2 '26稀释股数5.44亿,一年前为5.41亿。
- 净债务 $433亿现金 + 短期投资 $140亿,含租赁债务 $573亿;一年前净债务 $482亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $101亿 | $91.7亿 | +9.7% |
| 毛利率 | 72.0% | 67.2% | +4.9 百分点 |
| 营业利润 | $35.1亿 | $26.4亿 | +32.9% |
| 营业利润率 | 35.0% | 28.8% | +6.1 百分点 |
| 净利润 | $23.8亿 | $14.3亿 | +65.9% |
| 稀释EPS | $4.37 | $2.65 | +64.9% |
| 经营现金流 | $40亿 | $22.8亿 | +75.5% |
| 资本支出 | $5.13亿 | $3.69亿 | +39.0% |
| 自由现金流 | $34.9亿 | $19.1亿 | +82.6% |
| R&D | $18.7亿 | $17.4亿 | +7.1% |
| 股权激励费用 | $1.65亿 | $1.57亿 | +5.1% |
实际 vs 一致预期
2026-08-04| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $101亿 | $94.3亿 | +6.7% |
| EPS(一致预期口径) | $6.29 | $5.62 | +11.9% |
来自2026-08-04发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Other Products | – | – | – | – | – | |
| Other products | $17亿 | – | 16.9% | – | – | |
| Prolia | $7.59亿 | -32.4% | 7.5% | – | – | |
| ENBREL | $5.8亿 | -4.0% | 5.8% | – | – | |
| Product and Service, Other | – | – | – | – | – | |
| Repatha | $9.53亿 | – | 9.5% | – | – | |
| Repatha (evolocumab) | – | – | – | – | – | |
| EVENITY | $7.14亿 | +37.8% | 7.1% | – | – | |
| Otezla | $4.91亿 | -20.6% | 4.9% | – | – | |
| TEPEZZA | $5.76亿 | +14.1% | 5.7% | – | – | |
| XGEVA | $3.52亿 | -33.8% | 3.5% | – | – | |
| Other revenues | $5.17亿 | – | 5.1% | – | – | |
| TEZSPIRE | $4.86亿 | +42.1% | 4.8% | – | – | |
| BLINCYTO | $4.72亿 | +22.9% | 4.7% | – | – | |
| Nplate | $4.3亿 | +16.5% | 4.3% | – | – | |
| KRYSTEXXA | $4亿 | +14.6% | 4.0% | – | – | |
| Kyprolis | – | – | – | – | – | |
| Aranesp | $3.52亿 | -1.9% | 3.5% | – | – | |
| Vectibix | $3.38亿 | +10.8% | 3.4% | – | – | |
| UPLIZNA | $3.35亿 | – | 3.3% | – | – | |
| KYPROLIS | $3.14亿 | – | 3.1% | – | – | |
| IMDELLTRA/IMDYLLTRA | $2.88亿 | – | 2.9% | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $69.9亿 | +10.5% | 73.3% | – | – | |
| Non-US | $25.5亿 | +4.1% | 26.7% | – | – |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $125亿
- 资本支出
- -$23亿
- 股票回购
- $0
- 股息
- -$52.9亿
- 收购
- -$5300万
- 债务净发行
- $13.2亿
- 股权激励费用
- $4.92亿
- 自由现金流
- $102亿
- 股东回报 / FCF
- 51.9%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 28.7× | 24.7× | 21.6× – 34.2× |
| EV / EBITDA | 16.8× | 13.8× | 13.1× – 14.2× |
| EV / 营收 | 7.7× | 6.3× | 5.7× – 7.4× |
| 股价 / FCF | 24.8× | 17.5× | 13.6× – 21.7× |
| 股价 / 净资产 | 21.5× | 25.4× | 19.1× – 38.6× |
| FCF收益率 | 4.0% | 5.9% | 4.6% – 7.4% |
| 投入资本回报率 | 14.2% | 12.2% | 8.4% – 16.7% |
| 净资产收益率 | 89.3% | 106.7% | 69.6% – 179.0% |
分析师
一致目标价 $403.79 (-13.4%)
区间 $230.00 – $500.00 · 评级 Buy
强烈买入0
买入22
持有16
卖出3
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $390亿 | +6.1% | $23.06 | +62.0% | 20.2× | 19 |
| FY2027 | $405亿 | +3.8% | $24.51 | +6.3% | 19.0× | 19 |
| FY2028 | $419亿 | +3.4% | $25.94 | +5.8% | 18.0× | 11 |
| FY2029 | $435亿 | +4.0% | $27.75 | +7.0% | 16.8× | 4 |
| FY2030 | $455亿 | +4.5% | $29.74 | +7.2% | 15.7× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Amgen Inc.在近期10-Q / 10-K文件中标记的全部237项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $28.7亿 | $30.1亿 | -4.8% | $23.7亿 | $19.1亿 | +24.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $102亿 | $87亿 | +17.5% | $95.7亿 | $67.8亿 | +41.1% |
| Accrued Income Taxes, Current | $3.79亿2025-12-31 | $25.8亿 | -85.3% | $3.79亿 | $25.8亿 | -85.3% |
| Accrued Liabilities, Current | $172亿 | $150亿 | +14.4% | $185亿 | $176亿 | +5.0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $94亿 | $108亿 | -13.0% | $111亿 | $104亿 | +7.0% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$1.19亿 | -$5.44亿 | +78.1% | -$2.58亿 | -$6600万 | -290.9% |
| Advertising Expense | – | – | – | $9.63亿 | $9.87亿 | -2.4% |
| Amortization of Intangible Assets | $8.9亿 | $11亿 | -19.1% | $43亿 | $48亿 | -10.4% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1.65亿 | $1.57亿 | +5.1% | $4.94亿 | $5.3亿 | -6.8% |
| Assets | $956亿 | $879亿 | +8.8% | $906亿 | $918亿 | -1.4% |
| Assets, Current | $350亿 | $267亿 | +30.8% | $291亿 | $290亿 | +0.1% |
| Assets, Fair Value Disclosure | $196亿 | $125亿 | +56.8% | $149亿 | $161亿 | -7.3% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | – | – | – | -$600万 | $1800万 | -133.3% |
| Business Combination, Contingent Consideration, Liability | $1.71亿 | $9000万 | +90.0% | $1.61亿 | $1.06亿 | +51.9% |
| Capitalized Contract Cost, Net | $2.72亿2025-12-31 | $2.27亿 | +19.8% | $2.72亿 | $2.27亿 | +19.8% |
| Cash | $5.74亿 | $5.42亿 | +5.9% | $6.04亿 | $4.87亿 | +24.0% |
| Cash and Cash Equivalents, at Carrying Value | $140亿 | $80.3亿 | +74.3% | $91.3亿 | $120亿 | -23.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $140亿 | $80.3亿 | +74.3% | $91.3亿 | $120亿 | -23.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $19.5亿 | -$7.82亿 | +349.5% | -$28.4亿 | $10.3亿 | -376.4% |
| Commercial Paper | $02025-12-31 | $0 | – | $0 | $0 | – |
| Common Stock, Dividends, Per Share, Declared | $0.00 | $2.38 | -100.0% | $9.66 | $9.13 | +5.8% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 27.5亿 | 27.5亿 | 0.0% | 27.5亿 | 27.5亿 | 0.0% |
| Common Stock, Shares, Outstanding | 5.41亿 | 5.38亿 | +0.4% | 5.39亿 | 5.37亿 | +0.4% |
| Common Stocks, Including Additional Paid in Capital | $341亿 | $337亿 | +1.2% | $340亿 | $335亿 | +1.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $24.5亿 | $11.2亿 | +118.6% | $75.2亿 | $43.1亿 | +74.3% |
| Cost of Goods and Services Sold | $28.1亿 | $30.1亿 | -6.6% | $120亿 | $129亿 | -6.4% |
| Costs and Expenses | $65.4亿 | $65.2亿 | +0.3% | $277亿 | $262亿 | +5.8% |
| Current Federal Tax Expense (Benefit) | – | – | – | $9.59亿 | $9.65亿 | -0.6% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $9.71亿 | $7.59亿 | +27.9% |
| Current Income Tax Expense (Benefit) | – | – | – | $19.7亿 | $17.6亿 | +11.8% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $3500万 | $3300万 | +6.1% |
| Debt Instrument, Face Amount | $40亿2026-03-31 | – | – | $45亿2017-12-31 | $67亿 | -32.8% |
| Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $13.2亿 | $13.3亿 | -1.1% | $13.1亿 | $13.6亿 | -4.0% |
| Debt Securities, Available-for-sale | $134亿 | $74.9亿 | +79.2% | $85.3亿 | $115亿 | -25.8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $134亿 | $74.9亿 | +79.2% | $85.3亿 | $115亿 | -25.8% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$4.65亿 | -$8.6亿 | +45.9% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$2.42亿 | -$3.6亿 | +32.8% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$7亿 | -$12.4亿 | +43.5% |
| Deferred Income Tax Liabilities, Net | $13亿 | $13.9亿 | -6.1% | $13.7亿 | $16.2亿 | -15.5% |
| Deferred Income Taxes and Tax Credits | -$2.91亿 | -$4.22亿 | +31.0% | -$7.21亿 | -$12.3亿 | +41.3% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $700万 | -$1800万 | +138.9% |
| Deferred Tax Assets, Equity Method Investments | $02025-12-31 | $100万 | -100.0% | $0 | $100万 | -100.0% |
| Deferred Tax Assets, Gross | $69.2亿2025-12-31 | $60亿 | +15.5% | $69.2亿 | $60亿 | +15.5% |
| Deferred Tax Assets, Net | $23.9亿2025-12-31 | $16.4亿 | +45.7% | $23.9亿 | $16.4亿 | +45.7% |
| Deferred Tax Assets, Net of Valuation Allowance | $56.2亿2025-12-31 | $49.8亿 | +13.0% | $56.2亿 | $49.8亿 | +13.0% |
| Deferred Tax Assets, Other | $3.49亿2025-12-31 | $3.61亿 | -3.3% | $3.49亿 | $3.61亿 | -3.3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $1.38亿2025-12-31 | $1.3亿 | +6.2% | $1.38亿 | $1.3亿 | +6.2% |
| Deferred Tax Assets, Tax Deferred Expense, Other | $2.18亿2025-12-31 | $2亿 | +9.0% | $2.18亿 | $2亿 | +9.0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $8.9亿2025-12-31 | $6.93亿 | +28.4% | $8.9亿 | $6.93亿 | +28.4% |
| Deferred Tax Assets, Valuation Allowance | $13亿2025-12-31 | $10.2亿 | +27.5% | $13亿 | $10.2亿 | +27.5% |
| Deferred Tax Liabilities, Financing Arrangements | $2.6亿2025-12-31 | $2.64亿 | -1.5% | $2.6亿 | $2.64亿 | -1.5% |
| Deferred Tax Liabilities, Gross | $32.4亿2025-12-31 | $33.4亿 | -3.0% | $32.4亿 | $33.4亿 | -3.0% |
| Deferred Tax Liabilities, Intangible Assets | $20.7亿2025-12-31 | $25.7亿 | -19.7% | $20.7亿 | $25.7亿 | -19.7% |
| Deferred Tax Liabilities, Inventory | $2800万2025-12-31 | $1.14亿 | -75.4% | $2800万 | $1.14亿 | -75.4% |
| Deferred Tax Liabilities, Investments | $4.22亿2025-12-31 | $0 | – | $4.22亿 | $0 | – |
| Deferred Tax Liabilities, Other | $2.71亿2025-12-31 | $2.44亿 | +11.1% | $2.71亿 | $2.44亿 | +11.1% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $1.92亿2025-12-31 | $1.43亿 | +34.3% | $1.92亿 | $1.43亿 | +34.3% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-01